Roche's Genentech to invest $750 million to double Oregon manufacturing site
Roche's Genentech announced a $750 million investment to expand its existing production facility in Oregon, with the goal of doubling its capacity.
The expanded site is expected to boost manufacturing output for the company's biologic products, strengthening its U.S. supply chain.
In a separate development, FDA nominee Heidi Overton's close ties to former President Trump have raised concerns that her political loyalty could hinder her confirmation process.
The column also noted broader industry issues, including ongoing estrogen patch shortages, as part of the current pharmaceutical landscape.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: Pharmalittle: We’re reading about a big Roche investment in the U.S., estrogen patch shortages, and more”
read at STAT ↗
comments(0)
5-min edit window · permanent after that